Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR

被引:1
|
作者
Muniz-Saenz-Diez, Javier [1 ]
Ezponda, Ana [2 ]
Caballeros, Meylin [3 ]
de la Fuente, Ana [4 ]
Gavira, Juan J. [1 ]
Bastarrika, Gorka [2 ]
机构
[1] Clin Univ Navarra, Dept Cardiol, Ave Pio XII 36, Pamplona 31007, Spain
[2] Clin Univ Navarra, Dept Radiol, Pamplona, Spain
[3] Clin Univ Navarra, Dept Radiol, Madrid, Spain
[4] Clin Univ Navarra, Dept Cardiol, Madrid, Spain
来源
关键词
Coronary artery disease; Myocardial perfusion; Regadenoson; Perfusion cardiac magnetic resonance; Drug safety; CORONARY-ARTERY-DISEASE; HEART-RATE RESPONSE; DIAGNOSTIC PERFORMANCE; A(2A) AGONIST; DOUBLE-BLIND; ADENOSINE; TRIAL; TOLERABILITY; TOLERANCE; MR;
D O I
10.1007/s10554-023-02877-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Owing to its pharmacodynamics and posology, the use of regadenoson for stress cardiac magnetic resonance (CMR) has potential advantages over other vasodilators. We sought to evaluate the safety, hemodynamic response and diagnostic performance of regadenoson stress-CMR in routine clinical practice. All regadenoson stress-CMR examinations performed between May 2017 and July 2020 at our institution were retrospectively reviewed. A total of 698 studies were included for the final analysis. A conventional stress/rest protocol was performed using a 1.5T MRI scanner (Magnetom Aera, Siemens Healthineers, Erlangen, Germany). Adverse events, clinical symptoms, and hemodynamic response were assessed. Diagnostic accuracy of the test was evaluated in patients who underwent invasive coronary angiography. Nearly half of patients (48.5%) remained asymptomatic. Most common clinical symptoms included dyspnea (137, 19.6%), chest pain (116, 16.6%) and flushing (44, 6.3%). Two patients (0.28%) could not complete the examination due to severe hypotension or unbearable chest pain. Overall, an increase in heart rate (HR) response (36.2% [IQR: 22.5?50.9]) and a decrease in systolic and diastolic blood pressure (BP) (median systolic BP response of -5% [IQR: -11.5-0.6]; median diastolic BP response of -6.3 mmHg [IQR: -13.4-0]) was observed. Patients with symptoms induced by regadenoson showed higher HR response (40.3%, IQR: 26.4?56.1 vs. 32.4%, IQR: 19-45.6, p < 0.001), whereas a blunted HR response was observed in diabetic (29.6%, IQR: 18.4?42 p < 0.001), obese (31.7%, IQR: 20.7?46.2 p = 0.005) and patients aged 70 years or older (32.9%, IQR: 22.6?43.1 p < 0.001). Overall, regadenoson stress-CMR showed 95.65% (IQ 91.49?99.81) sensitivity, 54.84% (IQ 35.71?73.97) specificity, 86.99% (IQ 82.74?94.68) positive predictive value, and 77.27% (IQ 57.49?97.06) negative predictive value for detecting significant coronary stenosis as compared with invasive coronary angiography. Regadenoson is a well-tolerated vasodilator that can be safely employed for stress perfusion CMR, with high diagnostic performance.
引用
收藏
页码:1765 / 1774
页数:10
相关论文
共 50 条
  • [41] Safety and Feasibility of Adenosine Stress CMR for CAV Detection in Orthotopic Heart Transplant Recipients
    Bisaccia, Giandomenico
    Licordari, Roberto
    Leo, Isabella
    La Vecchia, Giulia
    Perotto, Maria
    Procopio, Maria Cristina
    Gallina, Sabina
    Wong, Joyce
    Bucciarelli-Ducci, Chiara
    CIRCULATION, 2023, 148
  • [42] Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis
    Gurunanthan Palani
    Zehra Husain
    Rafael Cabrera Salinas
    Vanji Karthikeyan
    Aarthee S. Karthikeyan
    Karthik Ananthasubramaniam
    Journal of Nuclear Cardiology, 2011, 18 : 605 - 611
  • [43] The yield of stress perfusion CMR in asymptomatic diabetics
    h-Ici D.O.
    Hovasse T.
    Morice M.C.
    Louvard Y.
    Unterseeh T.
    Garot J.
    Journal of Cardiovascular Magnetic Resonance, 13 (Suppl 1)
  • [44] The Yield of Stress Perfusion CMR in Diabetic Patients
    Oh-Ici, D.
    Moynagh, A.
    Hovasse, T.
    Unterseeh, T.
    Louvard, Y.
    Morice, M. C.
    Garot, J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2012, 181 : S309 - S309
  • [45] Myocardial perfusion imaging with regadenoson stress in advanced lung disease
    Jussi Schultz
    Antti Saraste
    Journal of Nuclear Cardiology, 2020, 27 (3) : 912 - 914
  • [46] Regadenoson vs Adenosine : Evaluation of Heart Rate Response with During Myocardial Perfusion Test with Pharmacologic Stress
    Hernandez, G. Sabatel
    Roldan, I. Bolivar
    Falcon, M. Camacho
    Perez, P. De La Riva
    Moron, C. Calvo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S535 - S536
  • [47] Safety and tolerability of regadenoson for myocardial perfusion imaging - first Danish experience
    Pape, Marianne
    Zacho, Helle D.
    Aaroe, Jens
    Jensen, Svend Eggert
    Petersen, Lars J.
    SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2016, 50 (03) : 180 - 186
  • [48] ISCHAEMIA AND VIABILITY ASSESSMENT WITH ADENOSINE STRESS CMR IN HIGH RISK PATIENTS: SAFETY, FEASIBILITY AND TOLERABILITY
    Wilson, Catherine
    Carpenter, Alexander
    Dastidar, Amardeep Ghosh
    Rodrigues, Jonathan
    Ahmed, Nauman
    Baritussio, Anna
    Lawton, Chris Benny
    McAlindon, Elisa
    Bucciarelli-Ducci, Chiara
    HEART, 2015, 101 : A17 - A18
  • [49] Safety of regadenoson stress testing in patients with pulmonary hypertension
    Victor M. Moles
    Thomas Cascino
    Ashraf Saleh
    Krasimira Mikhova
    John J. Lazarus
    Michael Ghannam
    Hong J. Yun
    Matthew Konerman
    Richard L. Weinberg
    Edward P. Ficaro
    James R. Corbett
    Vallerie V. McLaughlin
    Venkatesh L. Murthy
    Journal of Nuclear Cardiology, 2018, 25 : 820 - 827
  • [50] Safety of regadenoson for vasodilation in cardiac MRI stress tests
    Bastarrika, G.
    Ezponda, A.
    Garcia Baizan, A.
    Calvo, M.
    Pueyo, J. C.
    Gavira, J. J.
    Caballeros, M.
    RADIOLOGIA, 2020, 62 (03): : 213 - 221